VEGFA and breast carcinoma: Preclinical studies using in vitro breast cancer cell models and in vivo xenograft models have demonstrated that natural compounds such as Xian-ling-lian-xia-fang and Sinomenine may inhibit VM by downregulating VM-associated pathways, including VEGF-A/MMP2 and the miR-340-5p/SIAH2 axis, respectively [89, 108].